Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Spire Wealth Management bought a new position in Novavax, Inc. (NASDAQ:NVAX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Novavax is expected to post a loss of $0.67 per share ...

Get Novavax alerts: Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $19.00 target price on shares of ...

This makes it worthwhile to examine what the stock has in store. Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate ...

Moderna, whose stock fell around 23% Monday morning ... this as an opportunity to buy more shares at a discounted price. Shares of Novavax have gained 94.47% year to date. This compares to ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For the current quarter, Novavax is expected to post a ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...